Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.

@article{Troost2007ProlactinRI,
  title={Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.},
  author={Pieter W. Troost and Bertine E Lahuis and Mirjam H. A. Hermans and Jan K. Buitelaar and Herman van Engeland and Lawrence Scahill and Ruud B. Minderaa and Pieter J. Hoekstra},
  journal={Journal of clinical psychopharmacology},
  year={2007},
  volume={27 1},
  pages={52-7}
}
OBJECTIVE Little is known about the role of CYP2D6 polymorphism in risperidone-induced prolactin release in children. METHOD Twenty-five children (aged 5-15 years) with pervasive developmental disorders were genotyped for CYP2D6 polymorphisms. Serum prolactin, risperidone, and 9-hydroxyrisperidone were assessed at baseline and after 8 weeks of risperidone treatment (mean dosage, 0.06 +/- 0.03 mg/kg/d). After 24 weeks of treatment, prolactin was measured in a subsample of 15 children. Adverse… CONTINUE READING